Ukraine's Ministry Of Health Accepts Valion Bio's Regulatory Dossier For Entolimod For Formal Review Under Regulatory Equivalence Pathway
Valion Bio, Inc. (NASDAQ:VBIO) today announced that Ukraine's Ministry of Health (MoH) has accepted the Company's regulatory dossier for Entolimod—a medical countermeasure for Acute Radiation Syndrome (ARS)—for
Valion Bio's medicine for radiation sickness just moved forward in Ukraine—the government said it's ready to officially review it. This shows the company is making progress, though it's still early and approvals aren't guaranteed.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.